Esperion Expects Preferred Formulary Placement For Oral Cholesterol Drug Bempedoic Acid

29 Oct 2018

• By Emily Hayes

Final Phase III study for pivotal package of cholesterol drug bempedoic acid shows LDL-lowering efficacy and a clean safety profile, paving the way for filings in the first half of 2019.

Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.

Esperion Expects Preferred Formulary Placement For Oral Cholesterol Drug Bempedoic Acid

More from Cardiovascular

More from Therapy Areas